Research Roundup

OFFICIAL PUBLICATION OF

by its subsidiary APPco

Megan Haggan 29/09/2020

Debbie Rigby takes a look at the latest in research news Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure The EMPEROR-Reduced Trial compared empagliflozin (10 mg once daily) or placebo (in addition to recommended therapy) in 3730 patients with heart failure and an ejection fraction of 40% or less. Results show a lower risk

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

Full scope support could halt workforce crisis: review

expansion of scope of practice is the natural trend in contemporary era...

Benjamyn Sung

‘Consumer confusion, pharmacist frustration’ if current system continues

A good start but while we are still governed by a health system that enables each state to legislate their…

Karalyn Huxhagen

‘Consumer confusion, pharmacist frustration’ if current system continues

The first and foremost role of "expanded scope" is the HMR and collaborative medication management. A clear no brainer which…

Big Pharma

‘I can feel the walls closing in on me as this snowballs’

I'm yet to encounter a corporate provider, Debbie, with the benefits you describe around quality improvement with the corporate business…

Kelly Abbott

Research Roundup

Previous ‘Very, very lengthy delay’ torpedoes unfair dismissal case

Next COVID-19 and conduct: social media warning

In the beginning

The signs of ageing

Hyperpigmentation

How to avoid dry skin

MENU

Previous ‘Very, very lengthy delay’ torpedoes unfair dismissal case

Next COVID-19 and conduct: social media warning

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.